Pyxis Oncology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Pyxis Oncology, Inc. (PYXS) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value of $0.12 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue · last filed 2026-08-13
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2026-03-31 was $0.03, a 99.06% decline year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2025-03-31 was $3.18, a 24.22% increase year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2024-03-31 was $2.56.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2025 was $3.27, a 27.24% increase from fiscal 2024.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2024 was $2.57, a 17.63% decline from fiscal 2023.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2023 was $3.12, a 16.58% decline from fiscal 2022.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2022 was $3.74.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.12 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $0.03 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $3.27 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $3.26 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | $3.24 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $3.18 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $2.57 10-K · filed 2025-03-18 | |||
| 2024-09-30 | $2.57 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $2.56 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $2.56 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $3.12 10-K · filed 2024-03-21 | |||
| 2023-09-30 | $3.38 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $3.68 10-Q · filed 2023-08-11 | |||
| 2022-12-31 | $3.74 10-K · filed 2023-03-22 | |||
| 2022-09-30 | $3.60 10-Q · filed 2022-11-01 | |||
| 2022-06-30 | $3.58 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |